1. Home
  2. OXY vs NTRA Comparison

OXY vs NTRA Comparison

Compare OXY & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Occidental Petroleum Corporation

OXY

Occidental Petroleum Corporation

HOLD

Current Price

$59.06

Market Cap

54.3B

Sector

Energy

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$314.99

Market Cap

44.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OXY
NTRA
Founded
1920
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical Specialities
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
54.3B
44.7B
IPO Year
1995
2015

Fundamental Metrics

Financial Performance
Metric
OXY
NTRA
Price
$59.06
$314.99
Analyst Decision
Hold
Strong Buy
Analyst Count
21
15
Target Price
$57.71
$259.07
AVG Volume (30 Days)
8.0M
1.2M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
1.71%
N/A
EPS Growth
N/A
0.65
EPS
5.89
N/A
Revenue
$21,593,000,000.00
$210,939,000.00
Revenue This Year
$14.12
$18.08
Revenue Next Year
N/A
$19.65
P/E Ratio
$9.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$38.80
$156.71
52 Week High
$67.45
$326.03

Technical Indicators

Market Signals
Indicator
OXY
NTRA
Relative Strength Index (RSI) 59.19 67.71
Support Level $52.89 $186.96
Resistance Level $60.37 $326.03
Average True Range (ATR) 1.29 11.55
MACD 0.20 3.24
Stochastic Oscillator 79.97 87.46

Price Performance

Historical Comparison
OXY
NTRA

About OXY Occidental Petroleum Corporation

Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2025, the company reported net proved reserves of 4.6 billion barrels of oil equivalent. Net production averaged 1.4 million barrels of oil equivalent per day in 2025 at a ratio of roughly 74% oil and natural gas liquids and 26% natural gas.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: